Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-25
2007-12-25
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S227800, C514S230500, C514S231500, C514S248000, C514S252130, C514S255050, C514S266200, C544S050000, C544S058700, C544S092000, C544S149000, C544S238000, C544S286000, C544S374000, C548S212000, C548S235000, C548S204000, C548S180000
Reexamination Certificate
active
10926803
ABSTRACT:
Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds
REFERENCES:
patent: 5776718 (1998-07-01), Palmer et al.
patent: 6395897 (2002-05-01), Cywin et al.
patent: 6420364 (2002-07-01), Emmanuel et al.
patent: WO98/50533 (1998-05-01), None
patent: WO 99/24460 (1999-05-01), None
patent: WO 99/63115 (1999-12-01), None
patent: WO 00/55125 (2000-09-01), None
patent: WO 00/55126 (2000-09-01), None
patent: WO 00/69855 (2000-11-01), None
patent: WO 01/19796 (2001-03-01), None
patent: WO 01/19808 (2001-03-01), None
patent: WO 01/19816 (2001-03-01), None
Robin L. Thurmond, et al; Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor; Journal of Pharmacology and Experimental Therapeutics, vol. 308, No. 1 pp. 268-276.
H. Beck, et al; Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro; Eur. J. Immunol., 2001, 31: 3726-3736.
Robert W. Marquis;Inhibition of Cyst Ine Proteases;′Annual Reports in Medical Chemistry, Chapter 28, pp. 309-320.
Francesca Lazner, et al; Osteopetrosis and Osteoporosis: two sides of the same coin; Human Molecular Genetics 1999, vol. 8 No. 10 Review 1839-1846.
Galina K. Sukhova, et al; Expression of the Elastolytic Cathepsins S and K in Human Atheroma and Regulation of their Production in Smooth Muscle Cells; J. Clin. Invest. vol. 102, No. 2, Aug. 1998, pp. 576-583.
David Rasnick; Small Synthetic Inhibitors of Cysteine Proteases; Perspective in Drug Discovery and Design; vol. 6, pp. 47-63.
Ulf Mueller-Ladner, et al; Cysteine Proteinases in Arthritis and Inflammation; Perspectives in Drug Discovery and Design, vol. 6, pp. 87-98.
Charles A. Jameway et. al.;Immune Response in the Absence of Infection;Immuno Biology, Fourth Edition; Chapter 13, pp. 491-494.
Loren C. Karp, et al.;Ulcerative Colitis, Evidence for an Updated Hypothesis of Disease Pathogenesis;Mucosal Immunology (10 pages).
Gerold Schwarz;Cathepsin S. Activity is Detectable in Human Keratinocytes and is Selectively Upregulated upon Stimulation with Interferon-γ;The Society for Investigative Dermatology, Inc.;2002, pp. 44-49.
Bekkali Younes
Spero Denice Mary
Sun Sanxing
Ward Yancey David
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino Anthony P.
Dentz Bernard
Devlin Marry-Ellen M.
Morris Michael
LandOfFree
Pryanone compounds useful as reversible inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pryanone compounds useful as reversible inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pryanone compounds useful as reversible inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835760